Cargando…

1,25-Dihydroxy vitamin D3 treatment attenuates osteopenia, and improves bone muscle quality in Goto-Kakizaki type 2 diabetes model rats

PURPOSE: Osteopenia and skeletal fragility are considered to be the complications associated with type 2 diabetes mellitus (T2DM). The relationship between glucose metabolism, skeletal quality, and vitamin D have not been completely understood. We aimed to demonstrate a comprehensive bone quality pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Yanlong, Liu, Yanzhi, Lai, Wenxiu, Du, Minqun, Li, Shuhui, Zhou, Limin, Mo, Yulin, Wang, Pan, Min, Yalin, Cui, Liao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454079/
https://www.ncbi.nlm.nih.gov/pubmed/30826991
http://dx.doi.org/10.1007/s12020-019-01857-5
_version_ 1783409500704735232
author Liang, Yanlong
Liu, Yanzhi
Lai, Wenxiu
Du, Minqun
Li, Shuhui
Zhou, Limin
Mo, Yulin
Wang, Pan
Min, Yalin
Cui, Liao
author_facet Liang, Yanlong
Liu, Yanzhi
Lai, Wenxiu
Du, Minqun
Li, Shuhui
Zhou, Limin
Mo, Yulin
Wang, Pan
Min, Yalin
Cui, Liao
author_sort Liang, Yanlong
collection PubMed
description PURPOSE: Osteopenia and skeletal fragility are considered to be the complications associated with type 2 diabetes mellitus (T2DM). The relationship between glucose metabolism, skeletal quality, and vitamin D have not been completely understood. We aimed to demonstrate a comprehensive bone quality profile in a T2DM model subject and to investigate whether 1, 25-dihydroxy vitamin D3 could prevent osteopenia and skeletal fragility in the diabetes model rats. METHODS: Daily calcitriol (a 1, 25-dihydroxy vitamin D3 formulation, 0.045 μg/kg/day) treatment was administered to 21-week-old male Goto-Kakizaki (GK) rats (a genetic non-obese and non-insulin-dependent spontaneous diabetes rat model) for 20 weeks and the results were compared with those in untreated GK rats, and wild-type animals. RESULTS: Micro-computed tomography, histomorphometry, and bone mineral density analysis demonstrated that T2DM induced significant osteopenia, and impairment of bone microarchitecture and biomechanical properties in GK rats. T2DM also significantly decreased bone formation and increased bone resorption parameters in three regions of the skeleton (proximal tibia, mid-shaft of the tibia, and lumbar vertebrae), and increased carboxy-terminal type I collagen crosslinks, tartrate-resistant acid phosphatase, muscle ubiquitin C, and bone thioredoxin interacting protein (TXNIP) expression. Calcitriol treatment significantly alleviated bone loss, and improved bone microarchitecture and biomechanical properties and also decreased serum glucose and glycated serum protein levels. Biomarkers of bone formation were significantly increased, while muscle ubiquitin C and bone TXNIP expression were significantly decreased following calcitriol treatment. CONCLUSIONS: These results suggest that 1,25-dihydroxy vitamin D3 treatment effectively attenuates osteopenia, and improves bone and muscle quality in GK type 2 diabetes model rats.
format Online
Article
Text
id pubmed-6454079
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-64540792019-04-26 1,25-Dihydroxy vitamin D3 treatment attenuates osteopenia, and improves bone muscle quality in Goto-Kakizaki type 2 diabetes model rats Liang, Yanlong Liu, Yanzhi Lai, Wenxiu Du, Minqun Li, Shuhui Zhou, Limin Mo, Yulin Wang, Pan Min, Yalin Cui, Liao Endocrine Original Article PURPOSE: Osteopenia and skeletal fragility are considered to be the complications associated with type 2 diabetes mellitus (T2DM). The relationship between glucose metabolism, skeletal quality, and vitamin D have not been completely understood. We aimed to demonstrate a comprehensive bone quality profile in a T2DM model subject and to investigate whether 1, 25-dihydroxy vitamin D3 could prevent osteopenia and skeletal fragility in the diabetes model rats. METHODS: Daily calcitriol (a 1, 25-dihydroxy vitamin D3 formulation, 0.045 μg/kg/day) treatment was administered to 21-week-old male Goto-Kakizaki (GK) rats (a genetic non-obese and non-insulin-dependent spontaneous diabetes rat model) for 20 weeks and the results were compared with those in untreated GK rats, and wild-type animals. RESULTS: Micro-computed tomography, histomorphometry, and bone mineral density analysis demonstrated that T2DM induced significant osteopenia, and impairment of bone microarchitecture and biomechanical properties in GK rats. T2DM also significantly decreased bone formation and increased bone resorption parameters in three regions of the skeleton (proximal tibia, mid-shaft of the tibia, and lumbar vertebrae), and increased carboxy-terminal type I collagen crosslinks, tartrate-resistant acid phosphatase, muscle ubiquitin C, and bone thioredoxin interacting protein (TXNIP) expression. Calcitriol treatment significantly alleviated bone loss, and improved bone microarchitecture and biomechanical properties and also decreased serum glucose and glycated serum protein levels. Biomarkers of bone formation were significantly increased, while muscle ubiquitin C and bone TXNIP expression were significantly decreased following calcitriol treatment. CONCLUSIONS: These results suggest that 1,25-dihydroxy vitamin D3 treatment effectively attenuates osteopenia, and improves bone and muscle quality in GK type 2 diabetes model rats. Springer US 2019-03-02 2019 /pmc/articles/PMC6454079/ /pubmed/30826991 http://dx.doi.org/10.1007/s12020-019-01857-5 Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Liang, Yanlong
Liu, Yanzhi
Lai, Wenxiu
Du, Minqun
Li, Shuhui
Zhou, Limin
Mo, Yulin
Wang, Pan
Min, Yalin
Cui, Liao
1,25-Dihydroxy vitamin D3 treatment attenuates osteopenia, and improves bone muscle quality in Goto-Kakizaki type 2 diabetes model rats
title 1,25-Dihydroxy vitamin D3 treatment attenuates osteopenia, and improves bone muscle quality in Goto-Kakizaki type 2 diabetes model rats
title_full 1,25-Dihydroxy vitamin D3 treatment attenuates osteopenia, and improves bone muscle quality in Goto-Kakizaki type 2 diabetes model rats
title_fullStr 1,25-Dihydroxy vitamin D3 treatment attenuates osteopenia, and improves bone muscle quality in Goto-Kakizaki type 2 diabetes model rats
title_full_unstemmed 1,25-Dihydroxy vitamin D3 treatment attenuates osteopenia, and improves bone muscle quality in Goto-Kakizaki type 2 diabetes model rats
title_short 1,25-Dihydroxy vitamin D3 treatment attenuates osteopenia, and improves bone muscle quality in Goto-Kakizaki type 2 diabetes model rats
title_sort 1,25-dihydroxy vitamin d3 treatment attenuates osteopenia, and improves bone muscle quality in goto-kakizaki type 2 diabetes model rats
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454079/
https://www.ncbi.nlm.nih.gov/pubmed/30826991
http://dx.doi.org/10.1007/s12020-019-01857-5
work_keys_str_mv AT liangyanlong 125dihydroxyvitamind3treatmentattenuatesosteopeniaandimprovesbonemusclequalityingotokakizakitype2diabetesmodelrats
AT liuyanzhi 125dihydroxyvitamind3treatmentattenuatesosteopeniaandimprovesbonemusclequalityingotokakizakitype2diabetesmodelrats
AT laiwenxiu 125dihydroxyvitamind3treatmentattenuatesosteopeniaandimprovesbonemusclequalityingotokakizakitype2diabetesmodelrats
AT duminqun 125dihydroxyvitamind3treatmentattenuatesosteopeniaandimprovesbonemusclequalityingotokakizakitype2diabetesmodelrats
AT lishuhui 125dihydroxyvitamind3treatmentattenuatesosteopeniaandimprovesbonemusclequalityingotokakizakitype2diabetesmodelrats
AT zhoulimin 125dihydroxyvitamind3treatmentattenuatesosteopeniaandimprovesbonemusclequalityingotokakizakitype2diabetesmodelrats
AT moyulin 125dihydroxyvitamind3treatmentattenuatesosteopeniaandimprovesbonemusclequalityingotokakizakitype2diabetesmodelrats
AT wangpan 125dihydroxyvitamind3treatmentattenuatesosteopeniaandimprovesbonemusclequalityingotokakizakitype2diabetesmodelrats
AT minyalin 125dihydroxyvitamind3treatmentattenuatesosteopeniaandimprovesbonemusclequalityingotokakizakitype2diabetesmodelrats
AT cuiliao 125dihydroxyvitamind3treatmentattenuatesosteopeniaandimprovesbonemusclequalityingotokakizakitype2diabetesmodelrats